ALLERGAN INC's gross profit margin for the fourth quarter of its fiscal year 2014 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. ALLERGAN INC is extremely liquid. Currently, the Quick Ratio is 3.78 which clearly shows the ability to cover any short-term cash needs. AGN managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 19.95% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY14||Q4 FY13|
|Net Sales ($mil)||1910.5||1684.4|
|Net Income ($mil)||537.2||312.9|
|Balance Sheet||Q4 FY14||Q4 FY13|
|Cash & Equiv. ($mil)||4966.4||3649.1|
|Total Assets ($mil)||12415.7||10574.3|
|Total Debt ($mil)||2157.4||2153.9|
|Profitability||Q4 FY14||Q4 FY13|
|Gross Profit Margin||91.04||89.2|
|Return on Assets||12.27||9.31|
|Return on Equity||19.7||19.63|
|Debt||Q4 FY14||Q4 FY13|
|Share Data||Q4 FY14||Q4 FY13|
|Shares outstanding (mil)||299.23||297.61|
|Div / share||0.05||0.05|
|Book value / share||25.91||21.72|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2208065.0||3017720.0|
BUY. ALLERGAN INC's P/E ratio indicates a significant premium compared to an average of 31.57 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 19.50. Conducting a second comparison, its price-to-book ratio of 9.15 indicates a significant premium versus the S&P 500 average of 2.75 and a premium versus the industry average of 8.03. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, ALLERGAN INC proves to trade at a premium to investment alternatives within the industry.
|AGN 47.25||Peers 31.57||AGN 36.81||Peers 36.91|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
AGN is trading at a significant premium to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AGN is trading at a valuation on par to its peers.
|AGN 23.02||Peers 17.59||AGN 0.64||Peers 0.91|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
AGN is trading at a significant premium to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
AGN trades at a significant discount to its peers.
|AGN 9.15||Peers 8.03||AGN 19.52||Peers 32.47|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AGN is trading at a premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, AGN is expected to significantly trail its peers on the basis of its earnings growth rate.
|AGN 9.81||Peers 7.41||AGN 14.88||Peers 12.42|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AGN is trading at a significant premium to its industry.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
AGN has a sales growth rate that exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV